HAVCR2 and non-small cell lung carcinoma: For EGFR-positive NSCLC, the proportions were 40.00% (TIM3+/CD8+), 20.00% (TIM3-/CD8-), 7.50% (TIM3+/CD8-), and 32.50% (TIM3-/CD8+) (Figure 5B).